Noninvasive Small-Animal PET of Trastuzumab-Mediated EGFR Down-Regulation with 68Ga-Vec(fab’)2

Zhaofei Liu,Liyang Cui,Xujie Liu,Fan Wang

2012-01-01

Abstract:342 Objectives Previous studies have demonstrated that treatment of tumors expressing both epidermal growth factor receptor 1 (EGFR) and epidermal growth factor receptor 2 (HER2) with trastuzumab (Tras) resulted in increased EGFR homooligomerization and a subsequent rapid down-regulation. We investigated whether PET with 68Ga-Vec(Fab’)2, a 68Ga-labeled (Fab’)2 fragment of the anti-EGFR antibody panitumumab (Pani), could sensitively detect the early tumor response to Tras. Methods HT-29 cells were incubated with Tras with or without EGF stimulation, and then analyzed by 125I-Pani cell binding assay. HT-29 cells were incubated with 125I-Pani in the presence of increasing concentrations of Tras to determine the cross-reaction between the two antibodies. Vec(Fab’)2 was generated by enzymatic pepsin digestion, and then conjugated with 1,4,7-triazacyclononanetriacetic acid (NOTA) for 68Ga radiolabeling. MicroPET imaging and biodistribution studies of 68Ga-Vec(Fab’)2 were performed in HT-29 tumor-bearing mice with or without Tras treatment (5 mg/kg for 4 d). Results HT-29 cells expressed both EGFR and HER2. After Tras treatment, the EGFR expression level of HT-29 cells significantly decreased (125I-Pani binding cpm from 2414±142 to 1710±121). 125I-Pani binding to HT-29 cells was not displaced by increasing concentrations of Tras up to 10 μg/400 μL. The HT-29 tumors were clearly visualized with good contrast for 68Ga-Vec(Fab’)2 at 3 h p.i. After being treated with Tras, the HT-29 tumor uptake of 68Ga-Vec(Fab’)2 was much lower as compared with the untreated group. The quantified tumor uptake was 3.16±0.58, 1.35±0.31, and 0.78±0.21 %ID/g for control, Tras treatment, and cold Pani blocking, respectively. The tumor uptake value obtained from PET imaging had excellent linear correlation with the uptake value as measured by biodistribution. Conclusions 68Ga-Vec(Fab’)2 PET allows the sensitive detection of tumor EGFR down-regulation mediated by Tras. Future clinical investigation of 68Ga-Vec(Fab’)2 for early prediction and monitoring of the treatment efficacy of Tras is warranted